Pharmacological interventions for self-harm in adults

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 7, 2020, Pages

  Witt, Katrina G ^a,g   Hawton, Keith ^b   Hetrick, Sarah E ^c   Taylor Salisbury, Tatiana L ^d   Townsend, Ellen ^e   Hazell, Philip ^f  

^a THE NATIONAL CENTRE OF EXCELLENCE IN YOUTH MENTAL HEALTH   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; MOOD STABILIZER; NATURAL PRODUCT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTOMUTILATION; CLINICAL ASSESSMENT; DEPRESSION; DRUG EFFECT; HOPELESSNESS; HUMAN; INTERVENTION STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SOCIAL STATUS; SUICIDAL IDEATION; SYSTEMATIC REVIEW;

EID: 85088300774     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD013669     Document Type: Article

References (83)

1. Albrecht B, Staiger PK, Hall K, Miller P, Best D, Lubman DI. Benzodiazepine use and aggressive behaviour: a systematic review. Australian and New Zealand Journal of Psychiatry 2014;48:1096-114.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
3. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561.
4. Beck AT, Weissman A, Lester D, Trexler L. The measurement of pessimism: the Hopelessness Scale. Journal of Consulting and Clinical Psychology 1974;42:861-5.
5. Beck AT, Steet RA, Ranieri WF. Scale for Suicidal Ideation: psychometric properties of a self-report version. Journal of Clinical Psychology 1988;44:499-505.
6. Bergen H, Hawton K, Waters K, Cooper J, Kapur N. Epidemiology and trends in non-fatal self-harm in three centres in England, 2000-2007. British Journal of Psychiatry 2010;197:493-8.
7. Brunner J, Parhofer KG, Schwandt P, Bronisch T. Cholesterol, essential fatty acids, and suicide. Pharmacopsychiatry 2002;35:1-5.
8. Canner JK, Giuliano K, Selvaraiah S, Hammond ER, Schneider EB. Emergency department visits for attempted suicide and self harm in the USA, 2006-2013. Epidemiology and Psychiatric Services 2018;27:94-102.
9. Carroll R, Metcalfe C, Gunnell D. Hospital presenting self-harm and risk of fatal and non-fatal repetition: systematic review and meta-analysis. PLoS One 2014;9:e89944.
10. Carter G, Page A, Large M, Hetrick S, Milner AJ, Bendit N, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guideline for the management of deliberate self-harm. Australian and New Zealand Journal of Psychiatry 2016;50:939-1000.
11. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ 2013;346:f3646.
12. Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD003196.pub2]
13. Corcoran P, Griffin E, O'Carroll A, Cassidy L, Bonner B. Hospital-treated deliberate self-harm in the western area of Northern Ireland. Crisis 2015;36:83-90.
14. Courtney DB, Duda S, Szatmari P, Henderson J, Bennett K. Systematic review and quality appraisal of practice guidelines for self-harm in children and adolescents. Suicide and Life-Threatening Behavior 2019;49:707-23.
15. Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III. The issue of carry-over. Statistics in Medicine 2002;21:2161-73.
16. Curtin F, Altman DG, Elbourne D. Meta-analysis combining parallel and cross-over trials. I. Continuous outcomes. Statistics in Medicine 2002;21:2131-44.
17. De Beurs D, Vancayseele N, van Borkulo C, Portzky G, van Heeringen K. The association between motives, perceived problems and current thoughts of self-harm following an episode of self-harm: a network analysis. Journal of Affective Disorders 2018;240:262-70.
18. Deeks JJ, Higgins JPT, Altman DG, editor(s). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
19. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
20. Egger M, Smith GD, Schneider M, Christoph M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629.
21. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
22. US Food and Drug Administration. FDA approves new nasal spray medication for treatment-resistant depression. www.fda.gov/news-events/press-announcements/fda-approves-new-nasal-spray-medication-treatment-resistant-depression-available-only-certified Accessed 18 March 2020.
23. Feighner JP. Mechanism of action of antidepressant medications. Journal of Clinical Psychiatry 1999;60:s4-11.
24. Ferrari AJ, Norman RE, Freedman G, Baxter AJ, Pirkis JE, Harris MG, et al. The burden attributable to mental and substance use disorders as risk factors for suicide: findings from the Global Burden of Disease Study 2010. PLoS One 2014;9:e91936.
25. Fleiss JL. Measures of effect size for categorical data. In: Cooper H, Hedges LV, editors(s). The Handbook of Research Synthesis. New York, NY: Russell Sage Foundation, 1994.
26. Forte A, Buscaioni A, Fiorillo A, Pompii A, Baldessarini R. Suicidal risk following hospital discharge: a review. Harvard Review of Psychiatry 2019;27:209-16.
27. Geulayov G, Kapur N, Turnbull P, Clements C, Waters K, Ness J, et al. Epidemiology and trends in non-fatal self-harm in three centres in England, 2000-2012: findings from the Multicentre Study of Self-harm in England. BMJ Open 2016;6:e010538.
28. Geulayov G, Casey D, Bale L, Brand F, Clements C, Farooq B, et al. Suicide following presentation to hospital for non-fatal self-harm in the Multicentre Study of Self-Harm: a long-term follow-up study. Lancet Psychiatry 2019;6:1021-30.
29. Gjelsvik B, Heyerdahl F, Lunn D, Hawton K. Change in access to prescribed medication following an episode of deliberate self-poisoning: a multilevel approach. PLoS One 2014;9:e98086.
30. McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 26 June 2020.Available at gradepro.org.
31. Griffin E, Arensman E, Corcoran P, Wall A, Williamson E, Perry I. National Registry of Deliberate Self Harm Annual Report. Cork, Ireland: National Suicide Research Foundation, 2014.
32. Harrison JE, Henley G, AIHW. Suicide and hospitalised self-harm in Australia: trends and analysis. Injury research and statistics series no. 93. Cat. no. INJCAT 169. Canberra: AIHW 2014.
33. Hawton K, Hariss L, Hall S, Simkin S, Bale E, Bond A. Deliberate self-harm in Oxford, 1990-2000: a time of change in patient characteristics. Psychological Medicine 2003;33:987-96.
34. Hawton K, Harriss L. The changing gender ratio in occurrence of deliberate self-harm across the lifecycle. Crisis 2008;29:4-10.
35. Hawton K, Bergen H, Simkin H, Cooper K, Water K, Gunnell D, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. British Journal of Psychiatry 2010;196:354-8.
36. Hawton K, Saunders KEA, Topiwala A, Haw C. Psychiatric disorders in patients presenting to hospital following self-harm: a systematic review. Journal of Affective Disorders 2013;151:821-30.
37. Hawton K, Witt KG, Taylor Salisbury TL, Arensman E, Gunnell D, Hazell P, Townsend E, van Heeringen K. Psychosocial interventions for self-harm in adults. Cochrane Database of Systematic Reviews 2016;5:CD012189.
38. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
39. Higgins JPT, Eldridge S, Li T, editor(s). Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
40. Higgins JPT, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
41. Hopewell S, Loudon K, Clarke MJ, Oxman AD, Dickersin K. Publication bias in clinical trials due to statistical significance or direction of trial results. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.MR000006.pub3]
42. Kerry SM, Bland JM. Analysis of a trial randomised in clusters. BMJ 1998;316:54.
43. Klonsky ED. Non-suicidal self-injury in United States adults: prevalence, socio-demographics, topography and functions. Psychological Medicine 2011;41:1981-6.
44. Larkin C, di Blasi Z, Arensman E. Risk factors for repetition of self-harm: a systematic review of prospective hospital-based studies. PLoS One 2014;9:e84282.
45. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine 2009;6(7):e1000100.
46. Lilley R, Owens D, Horrocks J, House A, Noble R, Bergen H, et al. Hosptial care and repetition following self-harm: multicentre comparison of self-poisoning and self-injury. British Journal of Psychiatry 2008;192:440-5.
47. Mann JJ. The serotonergic system in mood disorders and suicidal behaviour. Philosophical Transactions of The Royal Society (B Biological Sciences) 2013;368:20120537.
48. Marshall M, Lockwood A, Bradley C, Adamns C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
49. Masiran R, Haniff J, Ali NH, Hamid AMA. Rates and profiles of self-harm presenting to Malaysian general hospitals: data from the Ministry of Health in 2011. Malaysian Journal of Medicine and Health Sciences 2017;13:39-45.
50. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13.
51. Morthorst BT, Soegaard B, Nordentoft M, Erlangsen A. Incidence rates of deliberate self-harm in Denmark, 1994-2011: a nationwide register study. Crisis 2016;37:256-64.
52. Murphy E, Kapur N, Webb R, Purandare N, Hawton K, Bergen H, et al. Risk factors for repetition and suicide following self-harm in older adults: multicentre cohort study. British Journal of Psychiatry 2012;200:399-404.
53. Müller A, Claes L, Brähler E, de Zwann M. Prevalence and correlates of self-harm in the German general population. PLoS One 2016;11:e0157928.
54. National Collaborating Centre for Mental Health. Clinical Guideline 16. Self-harm: The short-term physical and psychological management and secondary prevention of self-harm in primary and secondary care. London, UK: National Institute for Clinical Excellence, 2004.
55. National Institute for Health and Clinical Excellence. Self-harm: Longer-term management [National Clinical Practice Guideline Number 133]. Accessed 26 June 2020 from: https://www.nice.org.uk/guidance/cg133/evidence/full-guideline-pdf-184901581. London, UK: National Institute for Health and Clinical Excellence, 2011.
56. Owens D, Horrocks J, House A. Fatal and non-fatal repetition of self-harm: systematic review. British Journal of Psychiatry 2002;181:193-9.
57. Owens C, Fox F, Redwood S, Davies R, Foote L, Salisbury N, et al. Measuring outcomes in trials of interventions for people who self-harm: qualitative study of service users' views. British Journal of Psychiatry Open 2020;6:e22.
58. Perry IJ, Corcoran P, Fitzgerald AP, Keeley HS, Reulback U, Arensman E. The incidence and repetition of hospital-treated deliberate self-harm: findings from the world's first national registry. PLoS One 2012;7:e31663.
59. Plener PL, Brunner R, Fegert JM, Groschwitz RC, In-Albon T, Kaess M, et al. Treating nonsuicidal self-injury (NSSI) in adolescents: consensus based German guidelines. Child and Adolescent Psychiatry and Mental Health 2016;10:46.
60. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
61. Royal College of Psychiatrists. Managing Self-Harm in Young People (Guideline number CR192). London, UK: Royal College of Psychiatrists, 2014.
62. Sanacora G, Frye MA, McDonald W, Mathew SJ, Turner MS, Schatzberg AF, et al, the American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry 2017;74:399-405.
63. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.
64. Sinclair JMA, Gray A, Rivero-Arias O, Saunders KEA, Hawton K. Healthcare and social services resource use and costs of self-harm patients. Social Psychiatry and Psychiatric Epidemiology 2011;46:263-71.
65. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:I4898.
66. Stoffers J, Völlm BA, Rücker G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. Cochrane Database of Systematic Reviews 2010, Issue 6. [DOI: 10.1002/14651858.CD005653.pub2]
67. Sublette ME, Hibbeln JR, Galfalvy H, Oquendo MA, Mann JJ. Omega-3 polyunsaturated essential fatty acid status as a predictor of future suicide risk. American Journal of Psychiatry 2006;163:1100-02.
68. Tanskanen A, Hibbeln JR, Hintikka J, Haatainen K, Honkalampi K, Viinamaki H. Fish consumption, depression, and suicidality in a general population. Archives of General Psychiatry 2001;58:512-3.
69. Ting SA, Sulivan AF, Boudreaux ED, Miller I, Camargo CA. Trends in US emergency department visits for attempted suicide and self-inflicted injury, 1993-2008. General Hospital Psychiatry 2012;34:557-65.
70. Torgerson D. The use of Zelen's design in randomised trials. British Journal of Obstetrics and Gynaecology 2004;111:2.
71. Tsiachristas A, McDaid D, Casey D, Brand F, Leal J, Park A-L, et al. General hospital costs in England of medical and psychiatric care for patients who self-harm: a retrospective analysis. Lancet 2017;4:759-67.
72. Tyrer P. Why benzodiazepine are not going away: commentary on benzodiazepines for anxiety disorders. Advances in Psychiatric Treatment 2012;18:259-62.
73. van Heeringen K, Mann JJ. The neurobiology of suicide. Lancet Psychiatry 2014;1:63-72.
74. Viechtbauer W, Cheung MW-L. Outlier and influence diagnostics for meta-analysis. Research Synthesis Methods 2020;1:112-25.
75. Weissman MM, Staff MHS. Social Adjustment Scale - Self-Report (SAS-SR) User's Manual. North Tonawanda, NY: Multi-Health Systems, 1999.
76. World Health Organization. Preventing Suicide: A Global Imperative. Geneva, Switzerland: World Health Organization, 2014.
77. Wilkinson S, Taylor G, Templeton L, Mistral W, Salter E, Bennett P. Admissions to hospital for deliberate self-harm in England 1995-2000: an analysis of Hospital Episode Statistics. Journal of Public Health 2002;24:179-83.
78. Wilkinson ST, Ballard ED, Bloch MH, Mathew SJ, Murrough JW, Feder A, et al. The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis. American Journal of Psychiatry 2018;175:150-8.
79. Witt K, Townsend E, Arensman E, Gunnell D, Hazell P, Taylor Salisbury T, et al. Psychosocial interventions for people who self-harm: methodological issues involved in trials to evaluate effectiveness. Archives of Suicide Research 2019 Jul 10 [Epub ahead of print]:1-62. [DOI: 10.1080/13811118.2019.1592043]
80. Witt K, Potts J, Hubers A, Grunebaum MF, Murrough JW, Loo C, et al. Ketamine for suicidal ideation in adults with psychiatric disorders: a systematic review and meta-analysis of treatment trials. Australian and New Zealand Journal of Psychiatry 2020;54:29-45.
81. Zahl DL, Hawton K. Repetition of deliberate self-harm and subsequent suicide risk: long-term follow-up study of 11 583 patients. British Journal of Psychiatry 2004;185:70-5.
82. Zigmond AS, Snaith RP. The Hospital Anxeity and Depression Scale. Acta Psychiatrica Scandinavica 1983;67:361-70.
83. Hawton K, Witt KG, Taylor Salisbury TL, Arensman E, Gunnell D, Hazell P, et al. Pharmacological interventions for self-harm in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD011777]